| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/IMT.13.49 |
| P698 | PubMed publication ID | 23725286 |
| P50 | author | Jacques-Olivier Pers | Q59698293 |
| Alain Saraux | Q66753982 | ||
| Divi Cornec | Q90690435 | ||
| Valérie Devauchelle-Pensec | Q47264269 | ||
| P2093 | author name string | Coralie Clodic | |
| P2860 | cites work | Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. | Q50566871 |
| Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. | Q51412493 | ||
| Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. | Q51893824 | ||
| Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren's syndrome. | Q52017280 | ||
| Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. | Q52892758 | ||
| Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. | Q53207213 | ||
| Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome. | Q54595044 | ||
| Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. | Q54664601 | ||
| Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. | Q55055463 | ||
| A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus | Q28254310 | ||
| Interleukin-17 and type 17 helper T cells | Q28256510 | ||
| Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 | ||
| Identification of alpha-fodrin as a candidate autoantigen in primary Sjögren's syndrome | Q28587895 | ||
| Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome | Q33372523 | ||
| Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins | Q33534690 | ||
| Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia | Q34186569 | ||
| American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort | Q34260251 | ||
| Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 | ||
| Analysis of somatic mutation in five B cell subsets of human tonsil | Q34328629 | ||
| Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases | Q34369159 | ||
| Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group | Q34523084 | ||
| BAFF AND APRIL: a tutorial on B cell survival | Q34994661 | ||
| Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome | Q35082778 | ||
| Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study | Q35605535 | ||
| Antimuscarinic antibodies in Sjögren's syndrome: where are we, and where are we going? | Q36275127 | ||
| Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an international Sjögren's syndrome registry | Q36677386 | ||
| Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis | Q36745666 | ||
| Is the blood B-cell subset profile diagnostic for Sjogren syndrome? | Q37284531 | ||
| B-cell tolerance breakdown in Sjögren's syndrome: focus on BAFF. | Q37748142 | ||
| Immunological profile in primary Sjögren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease | Q37748148 | ||
| New insights into the development of lymphoid tissues | Q37779724 | ||
| Disturbance of cytokine networks in Sjögren's syndrome | Q37899957 | ||
| B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment | Q38023016 | ||
| Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab | Q40403631 | ||
| Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype | Q40690538 | ||
| Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs | Q42196937 | ||
| Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial | Q43481756 | ||
| Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B cells | Q46098675 | ||
| Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study | Q46687348 | ||
| The weight of interleukin-6 in B cell-related autoimmune disorders | Q47191054 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 639-646 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | Immunotherapy | Q18713038 |
| P1476 | title | The future of B cell-targeted therapies in Sjögren's syndrome | |
| P478 | volume | 5 |
| Q38818670 | A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells |
| Q46208181 | Adipose-Derived Mesenchymal Stem Cells Reduce Lymphocytic Infiltration in a Rabbit Model of Induced Autoimmune Dacryoadenitis |
| Q26796484 | B-cell survival factors in autoimmune rheumatic disorders |
| Q30948155 | Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy |
| Q92700230 | Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjögren's Syndrome |
| Q38222128 | The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review |
Search more.